ClinicalTrials.gg

Program

bimekizumab

Also written as “Bimekizumab”, “Bimekizumab regimen 1 iv” and “Bimekizumab regimen 2 iv”.

Its studies are mostly in Arthritis, Psoriatic · Psoriasis · Hidradenitis Suppurativa · Spondylitis, Ankylosing · Axial Spondyloarthritis, led by UCB.

Furthest: phase 3, since Dec 7, 201743 company-led studies, 7 open or runningNext primary completion: Dec 21, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB437 open or runningphase 3since Dec 7, 2017May 15, 2014Dec 21, 2026phase 3 · NCT06921850

Also a collaborator on its studies: parexel and comac-medical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since May 15, 2014.

  1. Jan 18, 2021Phase 2 study in PsoriasisNCT04718896 · 41 enrolled · United States, Canada, Germany and more
  2. May 20, 2021Phase 3 study in Hidradenitis SuppurativaNCT04901195 · 658 enrolled · United States, Australia, Belgium and more
  3. Aug 20, 2021Phase 3 study in Moderate to Severe Plaque PsoriasisNCT05020249 · 47 enrolled · Korea, Republic of
  4. Aug 25, 2021Phase 1 study in Healthy VolunteersNCT05028127 · 12 enrolled · United Kingdom
  5. Mar 14, 2022Phase 1 study in Healthy Study ParticipantsNCT05292131 · 121 enrolled · United States, Germany
  6. Aug 21, 2023Phase 3 study in PsoriasisNCT06011733 · 133 enrolled · China
  7. May 2, 2024Phase 3 study in PsoriasisNCT06425549 · 176 enrolled · United States, Belgium, Canada and more
  8. Jul 9, 2024Phase 3 study in Arthritis, PsoriaticNCT06506916 · 89 enrolled · United States, Germany, Poland
  9. Sep 30, 2024Phase 3 study in Arthritis, PsoriaticNCT06624228 · 553 enrolled · United States, Australia, Bulgaria and more
  10. Oct 30, 2024Phase 3 study in Arthritis, JuvenileNCT06668181 · 40 planned · Canada, France, Germany and more
  11. Mar 15, 2025Phase 1 study in Arthritis, PsoriaticNCT06888193 · 20 planned · United States, Canada, Germany and more
  12. Apr 3, 2025Phase 3 study in Hidradenitis SuppurativaNCT06921850 · 43 enrolled · United States, Germany, Poland
  13. Oct 17, 2025Phase 3 study in PsoriasisNCT07219420 · 320 planned · United States, Canada, China and more
  14. Dec 4, 2025Phase 1 study in Arthritis, PsoriaticNCT07290036 · 392 planned · United States, Bulgaria, Czechia and more

Ahead

  1. Dec 21, 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06921850
  2. Mar 9, 2027Primary completion: phase 3 study in Arthritis, PsoriaticNCT06506916
  3. Dec 27, 2027Primary completion: phase 3 study in PsoriasisNCT07219420
  4. Dec 31, 2027Primary completion: phase 1 study in Arthritis, PsoriaticNCT06888193

TargetBeta

IL17A →IL17F →read by rule
“Interleukin 17A inhibitor; Interleukin-17F inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
sonelokimabrulemoonlake-immunotherapeutics-agphase 312

Studies

All 43 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07290036Arthritis, Psoriatic · United States, Bulgaria, Czechia and more1RecruitingMay 18, 2028392
NCT07219420Psoriasis · United States, Canada, China and more3RecruitingDec 27, 2027320
NCT06921850Hidradenitis Suppurativa · United States, Germany, Poland3Active, not recruitingDec 21, 202643
NCT06888193Arthritis, Psoriatic · United States, Canada, Germany and more1RecruitingDec 31, 202720
NCT06668181Arthritis, Juvenile · Canada, France, Germany and more3RecruitingApr 12, 202840
NCT06624228Arthritis, Psoriatic · United States, Australia, Bulgaria and more3CompletedFeb 6, 2026553
NCT06506916Arthritis, Psoriatic · United States, Germany, Poland3Active, not recruitingMar 9, 202789
NCT06425549Psoriasis · United States, Belgium, Canada and more3Active, not recruitingAug 21, 2028176
NCT06011733Psoriasis · China3CompletedFeb 5, 2025133
NCT05292131Healthy Study Participants · United States, Germany1CompletedJan 9, 2023121
NCT05028127Healthy Volunteers · United Kingdom1CompletedJun 17, 201612
NCT05020249Moderate to Severe Plaque Psoriasis · Korea, Republic of3CompletedSep 5, 202247
NCT04901195Hidradenitis Suppurativa · United States, Australia, Belgium and more3CompletedJul 22, 2026658
NCT04718896Psoriasis · United States, Canada, Germany and more2CompletedMar 12, 202541
NCT04436640Axial Spondyloarthritis · United States, Belgium, Bulgaria and more3CompletedAug 9, 2026508
NCT04255862Healthy Study Participants · Germany1TerminatedApr 26, 202171
NCT04242498Hidradenitis Suppurativa · United States, Australia, Bulgaria and more3CompletedNov 9, 2021509
NCT04242446Hidradenitis Suppurativa · United States, Australia, Belgium and more3CompletedApr 7, 2022505
NCT04109976Arthritis, Psoriatic · United States, Czechia, Germany and more3CompletedNov 5, 2020214
NCT04009499Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedMay 26, 20261,131
NCT03928743Spondylitis, Ankylosing · United States, Belgium, Bulgaria and more3CompletedSep 3, 2021332
NCT03928704Axial Spondyloarthritis · United States, Belgium, Bulgaria and more3CompletedJun 29, 2022274
NCT03895385Healthy Volunteers · United States1CompletedOct 4, 201956
NCT03895203Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedAug 17, 2021852
NCT03896581Arthritis, Psoriatic · United States, Australia, Canada and more3CompletedDec 8, 2021400
NCT03766685Psoriasis · United States, Canada3CompletedJul 14, 2020172
NCT03707717Healthy Volunteers · United States, Germany1CompletedJun 5, 2019189
NCT03598790Psoriasis · United States, Australia, Belgium and more3CompletedNov 14, 20231,353
NCT03412747Psoriasis · United States, Australia, Canada and more3CompletedFeb 7, 2019478
NCT03410992Arthritis, Psoriatic · United States, Australia, Canada and more3CompletedDec 28, 2018435
NCT03370133Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedJan 8, 2019567
NCT03355573Spondylitis, Ankylosing · United States, Bulgaria, Canada and more2CompletedOct 19, 2022255
NCT03347110Arthritis, Psoriatic · United States, Czechia, Germany and more2CompletedOct 29, 2020184
NCT03248531Hidradenitis Suppurativa · United States, Australia, Belgium and more2CompletedNov 23, 201890
NCT03230292Psoriasis · United States, Australia, Canada and more2CompletedMar 6, 201943
NCT03215277Spondylitis, Ankylosing · United States, Czechia, Germany and more2CompletedMay 25, 202076
NCT03025542Psoriasis · United States, Australia, Canada and more2CompletedDec 11, 201749
NCT03010527Psoriasis · United States, Canada, Czechia and more2CompletedSep 25, 2018217
NCT02969525Arthritis, Psoriatic · United States, Czechia, Germany and more2CompletedNov 2017206
NCT02963506Spondylitis, Ankylosing · United States, Bulgaria, Canada and more2CompletedOct 2017303
NCT02905006Psoriasis · United States, Canada, Czechia and more2CompletedJun 2017250
NCT02529956Psoriasis · United Kingdom1CompletedJan 201439
NCT02141763Arthritis, Psoriatic · Bulgaria, Moldova, Republic of, United Kingdom1CompletedAug 201553

How it is read

Names in the registry

  • “Bimekizumab”, 35 entries
  • “bimekizumab”, 5 entries
  • “Bimekizumab regimen 1 iv”, 1 entry
  • “Bimekizumab regimen 2 iv”, 1 entry
  • “UCB4940 40 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.